Durect Corp (NAS:DRRX)
$ 1.06 -0.07 (-6.19%) Market Cap: 32.90 Mil Enterprise Value: 23.96 Mil PE Ratio: 0 PB Ratio: 2.18 GF Score: 52/100

DURECT Corporation - Special Call Transcript

Nov 12, 2019 / 05:00PM GMT
Release Date Price: $20 (-4.76%)
Operator

Greetings. Welcome to KOL Call on DUR-928 Phase IIa Alcoholic Hepatitis Study Results, hosted by DURECT. (Operator Instructions) As a reminder, this call is being recorded.

I'll now turn the conference over to Jim Brown, President and CEO of DURECT. Mr. Brown, you may now begin.

James E. Brown
DURECT Corporation - Co-Founder, CEO, President & Director

Thank you. Well, hello, everyone, and welcome to our webcast and the DUR-928 that we're sending here from The Liver Meeting, which is just wrapping up here in Boston. Today, we announced positive results from our Phase IIa clinical trial of DUR-928 in alcoholic hepatitis patients. These results were given in a late-breaking presentation at the meeting this morning by Dr. Tarek Hassanein. Additionally, these studies' results were selected for inclusion in the Best of The Liver Meeting summary slide presentation in the alcoholic-related liver disease category. They were also summarized in the press release that can be found on our website, along with a copy of the slides that Dr. Hassanein and I will

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot